BG106115A - Синергичните ефекти на амлодипин и аторвастатин метаболит като база за комбинирана терапия - Google Patents

Синергичните ефекти на амлодипин и аторвастатин метаболит като база за комбинирана терапия Download PDF

Info

Publication number: BG106115A
Authority: BG; Bulgaria
Prior art keywords: pharmaceutical composition; amlodipine; organs; blood pressure; lipid
Prior art date: 1999-04-23

Application number

BG106115A

Other languages

Bulgarian (bg)

English (en)

Inventor

Preston Mason

Original Assignee

Preston Mason

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-23

Filing date

2001-11-16

Publication date

2002-11-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27494873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG106115(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-11-16 Application filed by Preston Mason filed Critical Preston Mason

2002-11-29 Publication of BG106115A publication Critical patent/BG106115A/bg

Links

XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical class C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title claims abstract description 82
229960000528 amlodipine Drugs 0.000 title claims description 110
230000002195 synergetic effect Effects 0.000 title claims description 21
238000002648 combination therapy Methods 0.000 title abstract description 5
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title 1
239000012528 membrane Substances 0.000 claims abstract description 73
108010007622 LDL Lipoproteins Proteins 0.000 claims abstract description 33
102000007330 LDL Lipoproteins Human genes 0.000 claims abstract description 33
208000029078 coronary artery disease Diseases 0.000 claims abstract description 26
230000003859 lipid peroxidation Effects 0.000 claims abstract description 21
230000001225 therapeutic effect Effects 0.000 claims abstract description 6
ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 139
150000002632 lipids Chemical class 0.000 claims description 66
239000008194 pharmaceutical composition Substances 0.000 claims description 61
239000003814 drug Substances 0.000 claims description 42
238000000034 method Methods 0.000 claims description 42
239000000203 mixture Substances 0.000 claims description 37
208000019622 heart disease Diseases 0.000 claims description 27
230000036772 blood pressure Effects 0.000 claims description 24
201000001320 Atherosclerosis Diseases 0.000 claims description 23
208000020446 Cardiac disease Diseases 0.000 claims description 20
230000003647 oxidation Effects 0.000 claims description 16
238000007254 oxidation reaction Methods 0.000 claims description 16
200000000007 Arterial disease Diseases 0.000 claims description 13
206010020772 Hypertension Diseases 0.000 claims description 12
229960004005 amlodipine besylate Drugs 0.000 claims description 11
230000007423 decrease Effects 0.000 claims description 11
-1 lipid peroxide Chemical class 0.000 claims description 11
208000010125 myocardial infarction Diseases 0.000 claims description 9
229940124597 therapeutic agent Drugs 0.000 claims description 7
206010003210 Arteriosclerosis Diseases 0.000 claims description 6
208000031226 Hyperlipidaemia Diseases 0.000 claims description 6
208000011775 arteriosclerosis disease Diseases 0.000 claims description 6
208000006011 Stroke Diseases 0.000 claims description 4
239000000654 additive Substances 0.000 claims description 4
210000000056 organ Anatomy 0.000 claims 23
206010019280 Heart failures Diseases 0.000 claims 7
208000010496 Heart Arrest Diseases 0.000 claims 2
230000003247 decreasing effect Effects 0.000 claims 2
230000003078 antioxidant effect Effects 0.000 abstract description 39
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract description 34
230000000694 effects Effects 0.000 abstract description 30
239000003963 antioxidant agent Substances 0.000 abstract description 20
235000006708 antioxidants Nutrition 0.000 abstract description 20
235000019165 vitamin E Nutrition 0.000 abstract description 18
239000011709 vitamin E Substances 0.000 abstract description 18
229930003427 Vitamin E Natural products 0.000 abstract description 17
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract description 17
229940046009 vitamin E Drugs 0.000 abstract description 17
150000003904 phospholipids Chemical class 0.000 abstract description 15
239000000126 substance Substances 0.000 abstract description 13
230000005764 inhibitory process Effects 0.000 abstract description 12
230000001590 oxidative effect Effects 0.000 abstract description 10
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract description 9
229960005370 atorvastatin Drugs 0.000 abstract description 9
230000006378 damage Effects 0.000 abstract description 9
239000000890 drug combination Substances 0.000 abstract description 8
230000004048 modification Effects 0.000 abstract description 7
238000012986 modification Methods 0.000 abstract description 7
229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract description 6
241000282414 Homo sapiens Species 0.000 abstract description 6
150000001875 compounds Chemical class 0.000 abstract description 6
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract description 6
208000024172 Cardiovascular disease Diseases 0.000 abstract description 5
210000005167 vascular cell Anatomy 0.000 abstract description 4
238000002050 diffraction method Methods 0.000 abstract description 2
235000020777 polyunsaturated fatty acids Nutrition 0.000 abstract description 2
230000003389 potentiating effect Effects 0.000 abstract description 2
230000004001 molecular interaction Effects 0.000 abstract 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 36
229940079593 drug Drugs 0.000 description 35
238000011282 treatment Methods 0.000 description 22
235000012000 cholesterol Nutrition 0.000 description 17
238000004519 manufacturing process Methods 0.000 description 12
238000002474 experimental method Methods 0.000 description 11
230000003993 interaction Effects 0.000 description 11
150000003254 radicals Chemical class 0.000 description 10
238000002441 X-ray diffraction Methods 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 9
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
229940127291 Calcium channel antagonist Drugs 0.000 description 8
239000002207 metabolite Substances 0.000 description 8
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 7
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
239000011575 calcium Substances 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
102000004895 Lipoproteins Human genes 0.000 description 6
108090001030 Lipoproteins Proteins 0.000 description 6
239000000480 calcium channel blocker Substances 0.000 description 6
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 6
229960003912 probucol Drugs 0.000 description 6
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
230000003143 atherosclerotic effect Effects 0.000 description 5
229910052791 calcium Inorganic materials 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
238000005502 peroxidation Methods 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 4
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 4
230000036523 atherogenesis Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
150000002430 hydrocarbons Chemical group 0.000 description 4
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 4
229960004844 lovastatin Drugs 0.000 description 4
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 4
AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 4
229950009116 mevastatin Drugs 0.000 description 4
BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 4
238000002156 mixing Methods 0.000 description 4
229940036132 norvasc Drugs 0.000 description 4
230000008569 process Effects 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
239000004322 Butylated hydroxytoluene Substances 0.000 description 3
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
108091006146 Channels Proteins 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
241000282412 Homo Species 0.000 description 3
206010037742 Rabies Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 3
230000004075 alteration Effects 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
229940095259 butylated hydroxytoluene Drugs 0.000 description 3
230000003185 calcium uptake Effects 0.000 description 3
230000000747 cardiac effect Effects 0.000 description 3
210000004351 coronary vessel Anatomy 0.000 description 3
238000011161 development Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000002792 vascular Effects 0.000 description 3
235000019154 vitamin C Nutrition 0.000 description 3
239000011718 vitamin C Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
RWNNRGBCWXOVAC-UHFFFAOYSA-N 1,4-bis[bis(aziridin-1-yl)phosphoryl]piperazine Chemical compound C1CN1P(N1CCN(CC1)P(=O)(N1CC1)N1CC1)(=O)N1CC1 RWNNRGBCWXOVAC-UHFFFAOYSA-N 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
208000014882 Carotid artery disease Diseases 0.000 description 2
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
208000032928 Dyslipidaemia Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010010234 HDL Lipoproteins Proteins 0.000 description 2
102000015779 HDL Lipoproteins Human genes 0.000 description 2
101000889990 Homo sapiens Apolipoprotein(a) Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
239000000232 Lipid Bilayer Substances 0.000 description 2
208000017170 Lipid metabolism disease Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
241000288906 Primates Species 0.000 description 2
229920005654 Sephadex Polymers 0.000 description 2
239000012507 Sephadex™ Substances 0.000 description 2
108010062497 VLDL Lipoproteins Proteins 0.000 description 2
229930003268 Vitamin C Natural products 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000002411 adverse Effects 0.000 description 2
238000002399 angioplasty Methods 0.000 description 2
230000000879 anti-atherosclerotic effect Effects 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
208000037876 carotid Atherosclerosis Diseases 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000002301 combined effect Effects 0.000 description 2
238000007887 coronary angioplasty Methods 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
229940127292 dihydropyridine calcium channel blocker Drugs 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
239000011888 foil Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
102000045903 human LPA Human genes 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
229910052759 nickel Inorganic materials 0.000 description 2
229960001597 nifedipine Drugs 0.000 description 2
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000037361 pathway Effects 0.000 description 2
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000009469 supplementation Effects 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
XUKUURHRXDUEBC-SVBPBHIXSA-N (3s,5s)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SVBPBHIXSA-N 0.000 description 1
206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
229940122642 Calcium channel agonist Drugs 0.000 description 1
108010089254 Cholesterol oxidase Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
206010014476 Elevated cholesterol Diseases 0.000 description 1
206010048554 Endothelial dysfunction Diseases 0.000 description 1
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical class CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000029549 Muscle injury Diseases 0.000 description 1
102000006386 Myelin Proteins Human genes 0.000 description 1
108010083674 Myelin Proteins Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
208000032594 Vascular Remodeling Diseases 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
206010047163 Vasospasm Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
235000020661 alpha-linolenic acid Nutrition 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000489 anti-atherogenic effect Effects 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
230000000923 atherogenic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
235000013734 beta-carotene Nutrition 0.000 description 1
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
239000011648 beta-carotene Substances 0.000 description 1
229960002747 betacarotene Drugs 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000000801 calcium channel stimulating agent Substances 0.000 description 1
OKLAEQBUDFSNDL-UHFFFAOYSA-N calcium;1,4-dihydropyridine Chemical compound [Ca].C1C=CNC=C1 OKLAEQBUDFSNDL-UHFFFAOYSA-N 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
230000007211 cardiovascular event Effects 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000000782 cerebellar granule cell Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
229910000365 copper sulfate Inorganic materials 0.000 description 1
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
208000026758 coronary atherosclerosis Diseases 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000009699 differential effect Effects 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000008694 endothelial dysfunction Effects 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000003631 expected effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000010006 flight Effects 0.000 description 1
239000003574 free electron Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
210000004565 granule cell Anatomy 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000003999 initiator Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000002608 intravascular ultrasound Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
229960004427 isradipine Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229960004488 linolenic acid Drugs 0.000 description 1
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
238000010630 lipid peroxidation (MDA) assay Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
210000001872 metatarsal bone Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000005012 myelin Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000009223 neuronal apoptosis Effects 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000004792 oxidative damage Effects 0.000 description 1
108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
238000007427 paired t-test Methods 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
230000004963 pathophysiological condition Effects 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
230000003617 peroxidasic effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000011546 protein dye Substances 0.000 description 1
238000010926 purge Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000004835 semi-empirical calculation Methods 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000012128 staining reagent Substances 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000003966 vascular damage Effects 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
239000003643 water by type Substances 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1
OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)
Pyrrole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BG106115A 1999-04-23 2001-11-16 Синергичните ефекти на амлодипин и аторвастатин метаболит като база за комбинирана терапия BG106115A (bg)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US13066599P	1999-04-23	1999-04-23
US14530599P	1999-07-23	1999-07-23
US15112199P	1999-08-27	1999-08-27
US16659299P	1999-11-19	1999-11-19
PCT/US2000/010465 WO2000064443A1 (en)	1999-04-23	2000-04-18	Synergistic effects of amlodipine and atorvastatin

Publications (1)

Publication Number	Publication Date
BG106115A true BG106115A (bg)	2002-11-29

Family

ID=27494873

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG106115A BG106115A (bg)	1999-04-23	2001-11-16	Синергичните ефекти на амлодипин и аторвастатин метаболит като база за комбинирана терапия

Country Status (30)

Country	Link
EP (1)	EP1173172B1 (is)
JP (1)	JP2002542289A (is)
KR (1)	KR20020024581A (is)
CN (1)	CN1351492A (is)
AP (1)	AP2001002324A0 (is)
AT (1)	ATE314846T1 (is)
AU (1)	AU4647000A (is)
BG (1)	BG106115A (is)
BR (1)	BR0010689A (is)
CA (1)	CA2370639A1 (is)
CZ (1)	CZ20013793A3 (is)
DE (1)	DE60025344T2 (is)
DK (1)	DK1173172T3 (is)
EA (1)	EA004435B1 (is)
EE (1)	EE200100555A (is)
ES (1)	ES2256005T3 (is)
HK (1)	HK1043741A1 (is)
HU (1)	HUP0201016A3 (is)
IL (1)	IL146085A0 (is)
IS (1)	IS6118A (is)
NO (1)	NO20015128L (is)
OA (1)	OA11870A (is)
PE (1)	PE20010055A1 (is)
PL (1)	PL351408A1 (is)
PT (1)	PT1173172E (is)
SK (1)	SK15382001A3 (is)
SV (1)	SV2002000058A (is)
TN (1)	TNSN00085A1 (is)
UY (1)	UY26118A1 (is)
WO (1)	WO2000064443A1 (is)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20030324A1 (es) *	2001-07-31	2003-04-03	Warner Lambert Co	Composiciones farmaceuticas de amlodipina y atorvastatina
CN100430057C (zh) *	2005-04-08	2008-11-05	石药集团中奇制药技术（石家庄）有限公司	左旋氨氯地平和阿托伐他汀的药物组合物
KR101467110B1 (ko) *	2013-08-01	2014-11-28	한국방송공사	코로나링을 구비한 지선애자

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5385929A (en) *	1994-05-04	1995-01-31	Warner-Lambert Company	[(Hydroxyphenylamino) carbonyl] pyrroles
GT199800127A (es) *	1997-08-29	2000-02-01		Combinaciones terapeuticas.

2000
- 2000-04-18 AP APAP/P/2001/002324A patent/AP2001002324A0/en unknown
- 2000-04-18 PL PL00351408A patent/PL351408A1/xx unknown
- 2000-04-18 JP JP2000613434A patent/JP2002542289A/ja not_active Withdrawn
- 2000-04-18 EA EA200101112A patent/EA004435B1/ru not_active IP Right Cessation
- 2000-04-18 EE EEP200100555A patent/EE200100555A/xx unknown
- 2000-04-18 IL IL14608500A patent/IL146085A0/xx unknown
- 2000-04-18 CN CN00807935A patent/CN1351492A/zh active Pending
- 2000-04-18 KR KR1020017013547A patent/KR20020024581A/ko not_active Withdrawn
- 2000-04-18 DE DE60025344T patent/DE60025344T2/de not_active Expired - Fee Related
- 2000-04-18 WO PCT/US2000/010465 patent/WO2000064443A1/en not_active Ceased
- 2000-04-18 CA CA002370639A patent/CA2370639A1/en not_active Abandoned
- 2000-04-18 ES ES00928200T patent/ES2256005T3/es not_active Expired - Lifetime
- 2000-04-18 HU HU0201016A patent/HUP0201016A3/hu unknown
- 2000-04-18 AU AU46470/00A patent/AU4647000A/en not_active Abandoned
- 2000-04-18 AT AT00928200T patent/ATE314846T1/de not_active IP Right Cessation
- 2000-04-18 DK DK00928200T patent/DK1173172T3/da active
- 2000-04-18 PT PT00928200T patent/PT1173172E/pt unknown
- 2000-04-18 EP EP00928200A patent/EP1173172B1/en not_active Expired - Lifetime
- 2000-04-18 BR BR0010689-5A patent/BR0010689A/pt not_active IP Right Cessation
- 2000-04-18 HK HK02105343.1A patent/HK1043741A1/zh unknown
- 2000-04-18 OA OA1200100272A patent/OA11870A/en unknown
- 2000-04-18 CZ CZ20013793A patent/CZ20013793A3/cs unknown
- 2000-04-18 SK SK1538-2001A patent/SK15382001A3/sk unknown
- 2000-04-19 PE PE2000000374A patent/PE20010055A1/es not_active Application Discontinuation
- 2000-04-21 TN TNTNSN00085A patent/TNSN00085A1/fr unknown
- 2000-04-24 UY UY26118A patent/UY26118A1/es unknown
- 2000-04-25 SV SV2000000058A patent/SV2002000058A/es unknown
2001
- 2001-10-19 NO NO20015128A patent/NO20015128L/no not_active Application Discontinuation
- 2001-10-19 IS IS6118A patent/IS6118A/is unknown
- 2001-11-16 BG BG106115A patent/BG106115A/bg unknown

Also Published As

Publication number	Publication date
EA004435B1 (ru)	2004-04-29
NO20015128D0 (no)	2001-10-19
DK1173172T3 (da)	2006-05-15
EA200101112A1 (ru)	2002-06-27
IS6118A (is)	2001-10-19
CZ20013793A3 (cs)	2002-05-15
EE200100555A (et)	2002-12-16
JP2002542289A (ja)	2002-12-10
AP2001002324A0 (en)	2001-12-31
HUP0201016A3 (en)	2003-03-28
KR20020024581A (ko)	2002-03-30
DE60025344D1 (de)	2006-03-30
BR0010689A (pt)	2002-02-19
SK15382001A3 (sk)	2002-05-09
PT1173172E (pt)	2006-05-31
HK1043741A1 (zh)	2002-09-27
ES2256005T3 (es)	2006-07-16
WO2000064443A1 (en)	2000-11-02
AU4647000A (en)	2000-11-10
EP1173172B1 (en)	2006-01-04
SV2002000058A (es)	2002-02-05
CN1351492A (zh)	2002-05-29
UY26118A1 (es)	2001-03-16
PL351408A1 (en)	2003-04-22
PE20010055A1 (es)	2001-01-30
TNSN00085A1 (fr)	2005-11-10
CA2370639A1 (en)	2000-11-02
EP1173172A1 (en)	2002-01-23
EP1173172A4 (en)	2002-08-07
ATE314846T1 (de)	2006-02-15
DE60025344T2 (de)	2006-09-28
OA11870A (en)	2006-03-27
WO2000064443A9 (en)	2002-08-29
IL146085A0 (en)	2002-07-25
HUP0201016A2 (hu)	2002-07-29
NO20015128L (no)	2001-12-20

Publication	Publication Date	Title
US7129265B2 (en)	2006-10-31	Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
KR100586754B1 (ko)	2006-06-08	지단백질 산화의 억제
Stein et al.	2016	Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients
KR100200467B1 (ko)	1999-06-15	콜레스테롤 저하제 및 ace 억제제로 이루어진 아테롬성 동맥경화증의 예방, 안정화 또는 경감용 조성물
Scott et al.	2004	Rosuvastatin: a review of its use in the management of dyslipidemia
IL185384A (en)	2008-06-05	Pharmacological compositions for lowering plasma lipoprotein (A) levels and lowering risk factors for cardiovascular disease
KR101494067B1 (ko)	2015-02-16	부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
Jorge et al.	1997	Rapid reversal of endothelial dysfunction in hypercholesterolaemic rabbits treated with simvastatin and pravastatin
Sherratt et al.	2019	Rosmarinic acid and its esters inhibit membrane cholesterol domain formation through an antioxidant mechanism based, in nonlinear fashion, on alkyl chain length
BG106115A (bg)	2002-11-29	Синергичните ефекти на амлодипин и аторвастатин метаболит като база за комбинирана терапия
Illingworth	1989	New horizons in combination drug therapy for hypercholesterolemia
Bernini et al.	1997	Effect of lacidipine on cholesterol esterification: in vivo and in vitro studies
Lapenna et al.	2001	Antioxidant activity of amiodarone on human lipoprotein oxidation
JP2002542289A5 (is)	2007-06-07
MXPA01010694A (en)	2002-06-05	Synergistic effects of amlodipine and atorvastatin
Grieve et al.	2000	Chylomicron remnants potentiate phenylephrine-induced contractions of rat aorta by an endothelium-dependent mechanism
MXPA00003200A (en)	2001-05-17	Inhibtion of lipoprotein oxidation
Weir et al.	1996	Experimental Myocardial Ischemia/Myocardial Infarction/Pulmonary Artery Constriction: Anorexic Agents Aminorex, Fenfluramine, and Dexfenfluramine Inhibit Potassium Current in Rat Pulmonary Vascular Smooth Muscle and Cause Pulmonary Vasoconstriction